Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck

Spread the love

Sun Pharmaceutical Industries Limited today announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIFTM. The territory of the licensing agreement will only cover India.

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries1, including the US, EU, Canada and Australia.

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, “Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavour to bring innovative medicines that fill a need gap. MDD is a serious and complicated disorder and VORTIDIFTM will serve as an important novel treatment option for patients in India.”

MDD is one of the leading cause of disability, affecting approximately 246 million people globally2 and 35 million people in India.3 MDD is characterised by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behaviour.4

Sun Pharma is ranked No. 1 by prescriptions and value amongst Neurologists & Psychiatrists in India (IMS MAT Jan 2022). With a strong product portfolio, Sun Pharma’s CNS division constantly strives to provide innovative solutions to patients and health care providers in India.

H. Lundbeck is a global pharmaceutical company specialising in brain diseases.

TM – All brand names and trademarks are the property of their respective owners.


1.     Lundbeck

2.     COVID-19 Mental Disorders Collaborators. Lancet. 2021 Nov 6;398(10312):1700-1712.

3.     Arvind BA, BMJ Open. 2019 Jun 27;9(6): e027250.

4.     Kelliny M,  Ther Clin Risk Manag. 2015;11:1193-1212. Published 2015 Aug 12.


Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Author

Leave a Reply

Your email address will not be published. Required fields are marked *